Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Debt to Equity (2017)

Aclaris Therapeutics has reported Debt to Equity over the past 1 years, most recently at $0.0 for Q4 2017.

  • Quarterly results put Debt to Equity at $0.0 for Q4 2017, changed N/A from a year ago — trailing twelve months through Dec 2017 was $0.0 (changed N/A YoY), and the annual figure for FY2017 was $0.0, changed.
  • Debt to Equity for Q4 2017 was $0.0 at Aclaris Therapeutics.
  • Over the last five years, Debt to Equity for ACRS hit a ceiling of $0.0 in Q4 2017 and a floor of $0.0 in Q4 2017.